1. Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know

3. Introduction

4. Pressing Issues for Primary Care

5. Burden of Migraine

6. Migraine: Increasing Disability

7. Primary Headache Disorders: Frequency Classification

8. Importance of the Headache Diary

9. ICHD-3 Criteria: Migraine Without Aura

10. Migraine and Not TTH or Cluster Headache

11. Migraine and Not Sinus Headache or Neck Problems

12. Considerations and Criteria for Offering Preventive Migraine Treatment

13. Migraine Frequency and Preventive Treatment: EMA Indications and Faculty Considerations

14. Chronic Migraine and Appropriate Preventive Treatment: CaMEO

15. Eurolight Study: Measuring the Impact of Headache in Europe

16. Use of Health Care and Use of Migraine Preventive Treatments in Eurolight

17. European Headache Federation Recommendations for Headache Health Care Service Organization

18. European Headache Federation Recommendations for Headache Health Care Service Organization (cont)

19. Challenges in Primary Care

20. Recommended Migraine Prevention Treatments

21. Effect of Preventive Drugs: Proportion of Patients With ≥ 50% Reduction in Headache Frequency

22. Adherence to Conventional Preventive Therapy

23. Antibody Binding to CGRP Receptor Complex: Target Specificity

24. Anti-CGRP mAbs: Characteristics

25. Anti-CGRP mAbs: Clinical Trial Outcomes

26. Migraine: Pain and Much More

27. Faculty Recommendations on the Role of the PCP in Migraine Management

28. Use of Anti-CGRP mAbs: Insight From Germany

29. Use of Anti-CGRP mAbs: Insight From Ireland

30. Anti-CGRP mAbs: Challenges in Implementation

31. Migraine Resources for PCPs

32. Concluding Remarks

33. Abbreviations